SCHEMBL4761981

SCHEMBL4761981

CCn1c(-c2nonc2N)nc2cncc(Nc3ccc(OC)cc3)c21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA5 O75582 17/20 0.59
ROCK1 Q13464 13/20 0.53
AKT1 P31749 9/20 0.53
AKT2 P31751 9/20 0.53
AKT3 Q9Y243 9/20 0.53
DYRK1A Q13627 3/20 0.52
RPS6KA1 Q15418 3/20 0.52
RPS6KB1 P23443 3/20 0.52
CDK2 P24941 2/20 0.52
ROCK2 O75116 2/20 0.48
GSK3A P49840 2/20 0.48
PRKACA P17612 2/20 0.48
GSK3B P49841 2/20 0.48
DAPK3 O43293 1/20 0.48
PRKD3 O94806 1/20 0.48
PIM1 P11309 1/20 0.48
MARK3 P27448 1/20 0.48
GRK5 P34947 1/20 0.48
CDK8 P49336 1/20 0.48
CLK2 P49760 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4718547 0.88 RPS6KA5 (0.63) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4718346 0.83 RPS6KA5 (0.62) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4717393 0.82 RPS6KA5 (0.60) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4714299 0.81 RPS6KA5 (0.59) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4714293 0.81 RPS6KA5 (0.59) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4717261 0.79 RPS6KA5 (0.68) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4762142 0.79 RPS6KA5 (0.57) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL6644206 0.77 RPS6KA5 (0.68) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4000617 0.76 RPS6KA5 (0.58) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4761335 0.76 RPS6KA5 (0.62) RPS6KA5ROCK1AKT1AKT2AKT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689393-A4 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-12-17 EP claimed
US-20070123561-A1 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors LEE DENNIS 2007-05-31 US claimed
JP-2007507547-A 2007-03-29 JP claimed
EP-1689393-A2 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2006-08-16 EP claimed
WO-2005037198-A2 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123561-A1 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors TNK2, CDC42BPB, CDC42BPA RPS6KA5 117/4885ROCK1 4/4885AKT1 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.